Donor immune cells take on Hard-to-Treat cancers in early trial
NCT ID NCT05239143
First seen Nov 06, 2025 · Last updated Jun 22, 2026 · Updated 39 times
Summary
This early-phase trial is testing a new type of cell therapy called P-MUC1C-ALLO1 for people with advanced solid tumors (like breast, ovarian, lung, or pancreatic cancer) that have not responded to other treatments. The therapy uses donor immune cells engineered to recognize and attack cancer cells. The main goals are to find a safe dose and see if the treatment can shrink tumors. About 180 adults are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Center of Kansas
Wichita, Kansas, 67214, United States
-
Cedars Sinai Medical Center
Los Angeles, California, 90048, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Montefiore Medical Center
The Bronx, New York, 10467, United States
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, 80218, United States
-
University of California, Irvine Medical Center
Irvine, California, 92868, United States
-
University of California, San Diego
San Diego, California, 92037, United States
-
University of California, San Francisco
San Francisco, California, 94143, United States
-
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242, United States
-
University of Kansas Cancer Center
Westwood, Kansas, 66205, United States
-
University of Maryland Cancer Center
Baltimore, Maryland, 21201, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
P-MUC1C-ALLO1 CAR-T cells (a type of immune cell therapy made from donor cells, designed to attack cancer cells that have a protein called MUC1-C)
What this could lead to
If this works, it could point toward a new treatment option for several hard-to-treat cancers that have spread or come back.
What could go wrong
This is a very early (Phase 1) trial with only 180 people, so it is mainly checking safety and dosing. The therapy may not shrink tumors, and there could be serious side effects like cytokine release syndrome or immune reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.